Clinical trial
Double-blind, Randomized Trial to Investigate the Antihypertensive and Metabolic Effects of Candesartan in Insulin-resistant Obese Patients With a Hypertension Not Adequately Controlled by Previous ß-blocker or Calcium Channel Blocker
NCT00775814 is registered in ClinicalTrials.gov with Takeda as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Double-blind, Randomized Trial to Investigate the Antihypertensive and Metabolic Effects of Candesartan in Insulin-resistant Obese Patients With a Hypertension Not Adequately Controlled by Previous ß-blocker or Calcium Channel Blocker
- Lead sponsor
- Takeda
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- October 31, 2006
- Completion date
- September 30, 2008
- Enrollment
- 188 (actual)
- Sites
- 24
Conditions
As the registry lists them; a condition with its own page is linked.